Indoco Remedies Ltd — Q1 FY27 earnings call
Summary generated by AI from the official transcript Indoco Remedies Ltd filed with BSE on 04 Aug 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Indoco Remedies reported standalone revenue growth of 5.8% year-on-year to Rs 4,081 million in Q1 FY27, with consolidated revenue up 8.2% to Rs 4,662 million. Standalone EBITDA margin expanded to 10.3% from 3.8% a year earlier, aided by cost efficiency measures including a reduction in headcount and fewer manufacturing batches. Management discussed regulatory approvals across its Baddi and Goa facilities, a pending USFDA audit for its sterile plant, and flat performance in European and emerging markets which it attributed to timing and one-off factors.
1 statement from this call is not shown because its supporting quote could not be reproduced within our quoting limits. Nothing shown here is affected: every statement on this page carries its verified quote.
Numbers mentioned
Standalone revenue: INR4,081 million (Q1 FY27)
p. 3
“During Q1 FY27, our stand-alone operational revenue grew by 5.8% year-on-year to INR4,081 million, with consolidated revenue reaching INR4,662 million, up by 8.2% year-on-year.”
Aditi Panandikar, page 3 of the filed PDF · View the filing
Standalone EBITDA margin: 10.3% (Q1 FY27)
p. 3
“Standalone EBITDA saw expansion to INR422 million, delivering an EBITDA margin of 10.3%.”
Aditi Panandikar, page 3 of the filed PDF · View the filing
Consolidated EBITDA margin: 8.8% (Q1 FY27)
p. 5
“Consolidated EBITDA to net sales for the quarter is 8.8% at INR410 million compared to 4.1% at INR175 million.”
Sundeep Bambolkar, page 5 of the filed PDF · View the filing
Domestic formulations revenue: INR2,040 million (Q1 FY27)
p. 5
“Revenues from domestic formulation business for the quarter are at INR2,040 million as compared to INR2,028 million for the same quarter last year.”
Sundeep Bambolkar, page 5 of the filed PDF · View the filing
US business revenue growth: 62.2% (Q1 FY27)
p. 5
“Revenues from the U.S. business for the quarter grew by 62.2% at INR459 million as against INR283 million.”
Sundeep Bambolkar, page 5 of the filed PDF · View the filing
Europe revenue growth: 2.5% (Q1 FY27)
p. 5
“Revenues from Europe for the quarter grew by 2.5% at INR650 million against INR635 million.”
Sundeep Bambolkar, page 5 of the filed PDF · View the filing
API business revenue growth: 42.4% (Q1 FY27)
p. 5
“Revenues from API business for the quarter grew by 42.4% at INR521 million as against INR366 million.”
Sundeep Bambolkar, page 5 of the filed PDF · View the filing
Total debt: INR930 crores (as of June 2026)
p. 7
“So, overall debt level remains at around INR930 crores now as against INR964 crores as of March '26.”
Pramod Ghorpade, page 7 of the filed PDF · View the filing
Warren Remedies OTC business revenue: INR34 crores (Q1 FY27)
p. 14
“So for the first quarter this year, the OTC business of Warren Remedies has delivered a top line of INR34 crores with a healthy growth.”
Aditi Panandikar, page 14 of the filed PDF · View the filing
Warren Remedies EBITDA: INR6 crores (Q1 FY27)
p. 15
“Yes. INR6 crores for Warren Remedies overall between API manufacturing and OTC sales.”
Aditi Panandikar, page 15 of the filed PDF · View the filing
Europe order book: in excess of INR250 crores
p. 9
“I think as of now, we have in excess of INR250 crores of orders in hand for execution.”
Aditi Panandikar, page 9 of the filed PDF · View the filing
A&P expenses (consolidated): INR30-plus crores (Q1 FY27)
p. 13
“So approximately in quarter 1 at consol level, we have about INR30-plus crores of advertisement and sales promotion.”
Pramod Ghorpade, page 13 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
EBITDA margin — double-digit margins · FY27
stated as an aspiration by Aditi Panandikar
p. 7
“That is what we are aiming for.”
Aditi Panandikar, page 7 of the filed PDF · View the filing
India business growth — higher single-digit to double-digit growth
stated as an aspiration by Aditi Panandikar
p. 6
“So, you should expect higher single-digit to double-digit growth in India business going forward.”
Aditi Panandikar, page 6 of the filed PDF · View the filing
COGS/gross margin impact — Q3
stated conditionally by Aditi Panandikar
p. 14
“I expect partly impact of this to continue a little bit into Q3.”
Aditi Panandikar, page 14 of the filed PDF · View the filing
Debt repayment — INR110 crores this year and another INR150 crores next year · this year and next year
stated firmly by Pramod Ghorpade
p. 11
“Our objective is to repay INR110 crores this year and another INR150 crores in next year.”
Pramod Ghorpade, page 11 of the filed PDF · View the filing
Capex — not more than INR50 crores · FY27
stated firmly by Aditi Panandikar
p. 16
“We are expecting just maintenance capex this year. On a total, we expect not to spend more than INR50 crores.”
Aditi Panandikar, page 16 of the filed PDF · View the filing
R&D spend — less than 5% of revenue
stated firmly by Pramod Ghorpade
p. 16
“R&D currently, we are less than 5% of our revenue is the R&D spend.”
Pramod Ghorpade, page 16 of the filed PDF · View the filing
Export business doubling target — doubling export business · 2 to 3 years
stated firmly by Aditi Panandikar
p. 9
“Yes. We are directly in line for that.”
Aditi Panandikar, page 9 of the filed PDF · View the filing
API sales from ORIC facility — improvement in API sales · Q4 this year
stated conditionally by Aditi Panandikar
p. 15
“I feel from probably Q4 this year, we should see some improvement in API sales coming out of ORIC facility.”
Aditi Panandikar, page 15 of the filed PDF · View the filing
Domestic and emerging market growth — 10% to 11% CAGR · next 2 to 3 years
stated as an aspiration by Sundeep Bambolkar
p. 17
“Domestic and emerging market, you mentioned about good growth, about 10% to 11% kind of CAGR in the next 2 to 3 years.”
Sundeep Bambolkar, page 17 of the filed PDF · View the filing
Oral solid product launches for Europe — a couple of launches · by Q4
stated firmly by Aditi Panandikar
p. 16
“So like I said, a couple of oral solid launches will come by Q4 for Europe.”
Aditi Panandikar, page 16 of the filed PDF · View the filing
USFDA audit for sterile plant
stated conditionally by Aditi Panandikar
p. 17
“So, we have been waiting for a U.S. audit for almost more than 6 months now, completely ready.”
Aditi Panandikar, page 17 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
No update yet, hopeful in coming months
Answered by Aditi Panandikar
Asked by Nirmam Mehta: Whether there is any update on the USFDA plant audit
p. 5
“No, we've not heard anything yet, but let's keep our fingers crossed, hopefully in the next couple of months.”
Aditi Panandikar, page 5 of the filed PDF · View the filing
Attributed to a one-off timing issue and high prior-year base, not fundamental weakness
Answered by Aditi Panandikar
Asked by Nirmam Mehta: Reasons for flat international revenue given Europe and emerging market softness
p. 6
“But if you look at the March, April in combined, then we are still doing a much better per month sales. But I'm sure this is only a temporary 1 quarter glitch.”
Aditi Panandikar, page 6 of the filed PDF · View the filing
Attributed to seasonal weakness in anti-infective and respiratory segments due to delayed rains
Answered by Aditi Panandikar
Asked by Nirmam Mehta: Reasons for flat domestic business performance
p. 6
“And this year, we did not get rains in June. So, there was almost a 1-month pushover.”
Aditi Panandikar, page 6 of the filed PDF · View the filing
Attributed to increased cost of goods due to the war situation impacting raw material pricing and availability
Answered by Aditi Panandikar
Asked by Nirmam Mehta: Reason for gross margin decline this quarter
p. 6
“Gross margins, this quarter, we had an impact of the increase in cost of goods because of the war situation.”
Aditi Panandikar, page 6 of the filed PDF · View the filing
Declined to give specifics before USFDA audit clarity
Answered by Aditi Panandikar
Asked by Sudarshan Padmanabhan: Outlook for U.S. launches and Vigamox product potential
p. 7
“So as I said, at this stage, it is better to not say anything about ophthalmics too much. I would wait for the USFDA audit to happen after which we should discuss more concretely numbers.”
Aditi Panandikar, page 7 of the filed PDF · View the filing
Primarily used to repay debt, with future consideration for brand acquisitions
Answered by Aditi Panandikar
Asked by Sudarshan Padmanabhan: Use of cash from the Ophthalmic divestment
p. 7
“So going forward, definitely, the company will look to invest in acquisition of brands possibly for India business. But at this point in our journey, it was more important to repay debt, I think.”
Aditi Panandikar, page 7 of the filed PDF · View the filing
Expects margins to keep improving quarter on quarter
Answered by Aditi Panandikar
Asked by Sudarshan Padmanabhan: Outlook on margin trajectory
p. 8
“So, we expect margins to keep improving quarter-onquarter from here on.”
Aditi Panandikar, page 8 of the filed PDF · View the filing
Confirmed on track
Answered by Aditi Panandikar
Asked by Kenil Mehta: Whether the target to double export business in 2-3 years is on track
p. 9
“Yes. We are directly in line for that.”
Aditi Panandikar, page 9 of the filed PDF · View the filing
Growth from India and emerging markets plus improving profitability in Europe and eventually U.S.
Answered by Aditi Panandikar
Asked by Kaustav Bubna: Key triggers to move operating profit above finance and depreciation cost
p. 10
“So as per me, from a scaling of operating profit angle, one should look at India and emerging steadily adding to it and one should expect increased profit coming from Europe.”
Aditi Panandikar, page 10 of the filed PDF · View the filing
Attributed to reduced headcount, fewer manufacturing batches, and divestment of ophthalmic division
Answered by Aditi Panandikar
Asked by Pratik Kothari: Sustainability of reduction in employee and other expenses
p. 11
“Quite honestly, close to 900 people have been reduced.”
Aditi Panandikar, page 11 of the filed PDF · View the filing
Europe is profitable; US sterile business not yet profitable due to remediation costs
Answered by Aditi Panandikar
Asked by Zain: Whether Europe and US businesses are EBITDA profitable
p. 17
“Europe, we are definitely profitable. But as I said, after Master Manufacturing Plan execution, in a couple of quarters, we should be able to see even more improvements happen.”
Aditi Panandikar, page 17 of the filed PDF · View the filing
No fixed timeline given; management remains hopeful of an early audit
Answered by Aditi Panandikar
Asked by Raghu Ram: Timeline for resolving USFDA issues
p. 17
“We are keeping fingers crossed for an early audit.”
Aditi Panandikar, page 17 of the filed PDF · View the filing
Risks flagged
Increased cost of goods due to war-related disruption in raw material pricing and availability
p. 6
“For this particular quarter, you see COGS impacted and almost by 2 percentage points, our cost of goods has gone up.”
Aditi Panandikar, page 6 of the filed PDF · View the filing
Delayed monsoon impacting seasonal respiratory and anti-infective product sales
p. 6
“And this year, we did not get rains in June. So, there was almost a 1-month pushover.”
Aditi Panandikar, page 6 of the filed PDF · View the filing
Pending USFDA audit delaying new product approvals for the sterile business
p. 7
“So as you know, for the sterile business, our new product approvals are held because of the U.S. audit, which is yet to happen.”
Aditi Panandikar, page 7 of the filed PDF · View the filing
Product availability and freight cost challenges in emerging markets due to war issues
p. 8
“Of course, there were challenges of product availability because of war issues.”
Aditi Panandikar, page 8 of the filed PDF · View the filing
US sterile business unable to deliver profits due to remediation costs
p. 17
“U.S., on the other hand, especially at the back of the remediation costs, etc., that business is not able to deliver profits as yet, especially the sterile part of it.”
Aditi Panandikar, page 17 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.